US pharma major Eli Lilly has launched in India its eagerly awaited diabetes and obesity drug Mounjaro (tripeptide). The launch of this breakthrough medicine is an important step toward dealing with India's increasing load of diabetes and obesity-related morbidity.
Mounjaro was able to stir international interest with its efficacy in treating type 2 diabetes and obesity, and can now be bought in India at a competitive price range. The medication comes in a vial of a single dose, with the cost of a 2.5 mg vial set at ₹3,500 and that of a 5 mg vial at ₹4,375. Individuals who take the drug weekly can budget anywhere between ₹14,000 and ₹17,500 per month, depending on their medication requirements.
In comparison to the United States, where the drug costs $1,000–$1,200 every month (around ₹86,000–1 lakh), the India-specific price highlights Lilly's dedication to making more sophisticated treatment available in the country.
How Mounjaro Works
According to the reports, Mounjaro is the first-of-its-kind medication that acts on both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptors. Stimulating these receptors, the medication increases insulin production, controls blood sugar levels, and aids in body weight loss, making it a potential answer for patients suffering from diabetes and obesity.
Also Read: Is Your Eye Twitching a Sign of Something Serious? Neurological and Lifestyle Causes Explained
Filling a Growing Health Gap
India has an estimated 101 million individuals with diabetes, with almost half of them having poor glycaemic control because of less than optimal treatment regimens. Obesity is also a major public health issue, with almost 100 million adults being affected, with a prevalence rate of about 6.5% as of 2023. For the unversed, obesity is associated with more than 200 health conditions, such as hypertension, coronary heart disease, and obstructive sleep apnea, further emphasising the necessity for effective medical interventions.
How Mounjaro Will Increase Access to Innovative Treatments
With approval from the Central Drugs Standard Control Organisation (CDSCO), the launch of Mounjaro in India marks an important milestone towards increasing treatment availability for patients grappling with diabetes and weight issues. With a breakthrough, dual-action therapy at an affordable local price point, Eli Lilly intends to bridge the treatment divide and enhance health outcomes for millions of Indians.
Bottomline
With increasing awareness and healthcare professionals adopting Mounjaro in treatment regimens, this groundbreaking drug can potentially revolutionise diabetes and obesity management in India, giving a glimmer of hope to those who require improved therapeutic solutions.